RESUMO
Metformin is widely used as a frontline medicine of type-II diabetes. Frequent overdose side-effects and their consequent adversative need to be reduced. The novel source of marine hydrozoa, Thyroscyphus ramosus derived chitosan combined metformin drug was administrated to evaluate the antidiabetic potential on a high-fat diet (HFD) with streptozotocin (STZ) induced diabetic rats. The primary analysis of In vitro antioxidant activity was tested for various solvent dissolved chitosan. Based on their IC50 dose values, CsnAA was chosen for further experiments. The chitosan was combined with metformin by sonication and confirmed through XRD, FTIR and SEM analysis. The enhanced activity was observed in 100 mg/kg metformin combined with CSN500mg/kg. The level of serum bilirubin, total protein, SGH, liver glycogen, Glucose-6-phosphatase and fructose-1,6- phosphatase values were significantly similar to metformin 300 mg/kg treated group. With this beneficiary, the novel chitosan was recommended to administrate with metformin to improve the drug efficacy and reduction of overdose lethal effects.
